98 related articles for article (PubMed ID: 26019036)
1. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
2. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.
Li B; Liu A; Wen Y; Yang G; Zhao J; Li X; Mao Y; Li B
J Clin Lab Anal; 2021 Sep; 35(9):e23932. PubMed ID: 34403527
[TBL] [Abstract][Full Text] [Related]
3. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
Moon AM; Weiss NS; Beste LA; Su F; Ho SB; Jin GY; Lowy E; Berry K; Ioannou GN
Gastroenterology; 2018 Oct; 155(4):1128-1139.e6. PubMed ID: 29981779
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.
Csepregi A; Ebert MP; Röcken C; Schneider-Stock R; Hoffmann J; Schulz HU; Roessner A; Malfertheiner P
BMC Cancer; 2010 Jun; 10():317. PubMed ID: 20569442
[TBL] [Abstract][Full Text] [Related]
5. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.
Wang K; Bai Y; Chen S; Huang J; Yuan J; Chen W; Yao P; Miao X; Wang Y; Liang Y; Zhang X; He M; Yang H; Guo H; Wei S
Cancer Med; 2018 Jun; 7(6):2691-2698. PubMed ID: 29696820
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of glycine dehydrogenase promoter in peripheral blood mononuclear cells is a new diagnostic marker of hepatitis B virus-associated hepatocellular carcinoma.
Miao LL; Wang JW; Liu HH; Gao S; Fan YC; Wang K
Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):35-42. PubMed ID: 36878837
[TBL] [Abstract][Full Text] [Related]
7. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.
Lin SY; Xia W; Kim AK; Chen D; Schleyer S; Choi L; Wang Z; Hamilton JP; Luu H; Hann HW; Chang TT; Hu CT; Woodard A; Gade TP; Su YH
Sci Rep; 2023 Dec; 13(1):21585. PubMed ID: 38062093
[TBL] [Abstract][Full Text] [Related]
8. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.
Wu HC; Yang HI; Wang Q; Chen CJ; Santella RM
Carcinogenesis; 2017 Oct; 38(10):1021-1028. PubMed ID: 28981677
[TBL] [Abstract][Full Text] [Related]
9. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma.
Tyson GL; Duan Z; Kramer JR; Davila JA; Richardson PA; El-Serag HB
Clin Gastroenterol Hepatol; 2011 Nov; 9(11):989-94. PubMed ID: 21820396
[TBL] [Abstract][Full Text] [Related]
10. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.
Kim SC; Kim DW; Cho EJ; Lee JY; Kim J; Kwon C; Kim-Ha J; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Kim W; Kim W; Kim H; Kim YJ; Yoon JH; Yu SJ; Kim YJ
Mol Cancer; 2023 Oct; 22(1):164. PubMed ID: 37803338
[TBL] [Abstract][Full Text] [Related]
11. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.
Iida H; Honda M; Kawai HF; Yamashita T; Shirota Y; Wang BC; Miao H; Kaneko S
Gut; 2005 Jun; 54(6):843-51. PubMed ID: 15888795
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
He D; Zhang X; Tu J
Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
[TBL] [Abstract][Full Text] [Related]
13. Association of APC Expression with Its Promoter Methylation Status and the Prognosis of Hepatocellular Carcinoma.
Xing W; Li Y; Chen J; Hu Q; Liu P; Ge X; Lv J; Wang D
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3851-3857. PubMed ID: 38019243
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy in Hepatocellular Carcinoma.
Zhou Z; Xu X; Liu Y; Liu Q; Zhang W; Wang K; Wang J; Yin Y
Methods Mol Biol; 2023; 2695():213-225. PubMed ID: 37450121
[TBL] [Abstract][Full Text] [Related]
15. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma.
Zhao Y; Zhao L; Jin H; Xie Y; Chen L; Zhang W; Dong L; Zhang L; Huang Y; Wan K; Yang Q; Wang S
Epigenetics; 2024 Dec; 19(1):2299044. PubMed ID: 38154055
[TBL] [Abstract][Full Text] [Related]
16. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng Z; Ji Y; Han B; Tan Z; Ren Y; Gao J; Chen N; Ma C; Zhang Y; Yao Y; Lu H; Huang H; Xu M; Chen L; Zheng L; Gu J; Xiong D; Zhao J; Gu J; Chen Z; Wang K
Genome Med; 2023 Nov; 15(1):93. PubMed ID: 37936230
[TBL] [Abstract][Full Text] [Related]
17. Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.
Kristiansen S; Nielsen D; Sölétormos G
Clin Epigenetics; 2016; 8():35. PubMed ID: 27042241
[TBL] [Abstract][Full Text] [Related]
18. Ras Association Domain Family 1A Gene Promoter Methylation as a Biomarker for Chronic Viral Hepatitis C-related Hepatocellular Carcinoma.
Abou Zeid AA; El-Sayed ET; Ahdy JK; Tawfik MR
Cureus; 2023 Sep; 15(9):e45687. PubMed ID: 37868533
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA and Hepatocellular Carcinoma.
Yang JD; Liu MC; Kisiel JB
Semin Liver Dis; 2019 Nov; 39(4):452-462. PubMed ID: 31226727
[TBL] [Abstract][Full Text] [Related]
20. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I; Suehiro Y; Yamauchi Y; Hoshida T; Tanabe N; Oono T; Kawamoto D; Nishimura T; Matsumoto T; Ishikawa T; Shimokawa M; Tamori A; Kawada N; Tamai Y; Iwasa M; Nakagawa H; Nagano H; Takami T; Yamasaki T
Hepatol Int; 2023 Oct; 17(5):1289-1299. PubMed ID: 37186217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
